Article Versions Notes

Hatano T, Tanei T, Seno S, Sota Y, Masunaga N, Mishima C, Tsukabe M, Yoshinami T, Miyake T, Shimoda M, et al. High HER2 Intratumoral Heterogeneity Is Resistant to Anti-HER2 Neoadjuvant Chemotherapy in Early Stage and Locally Advanced HER2-Positive Breast Cancer. Cancers. 2025; 17(13):2126. https://doi.org/10.3390/cancers17132126

Hatano, Takaaki, Tomonori Tanei, Shigeto Seno, Yoshiaki Sota, Nanae Masunaga, Chieko Mishima, Masami Tsukabe, Tetsuhiro Yoshinami, Tomohiro Miyake, Masafumi Shimoda, and et al. 2025. "High HER2 Intratumoral Heterogeneity Is Resistant to Anti-HER2 Neoadjuvant Chemotherapy in Early Stage and Locally Advanced HER2-Positive Breast Cancer" Cancers 17, no. 13: 2126. https://doi.org/10.3390/cancers17132126

Hatano, T., Tanei, T., Seno, S., Sota, Y., Masunaga, N., Mishima, C., Tsukabe, M., Yoshinami, T., Miyake, T., Shimoda, M., & Shimazu, K. (2025). High HER2 Intratumoral Heterogeneity Is Resistant to Anti-HER2 Neoadjuvant Chemotherapy in Early Stage and Locally Advanced HER2-Positive Breast Cancer. Cancers, 17(13), 2126. https://doi.org/10.3390/cancers17132126